Abstract submissions are invited for this Congress. The electronic abstracts submission site is open at www.hivglasgow.org

- ARV-based Prevention
  - Mother-to-child transmission; PEP; PrEP; Treatment as Prevention (TasP)
- Clinical Pharmacology
- Community Initiatives
- Co-morbidities and Complications of Disease and/or Treatment
  - Ageing; Bone; Cardiovascular; Malignancies (AIDS-defining and Non-AIDS-defining); Metabolic; Neurological; Renal; Other
- Late Presenters
- Models of Care
  - Cost-effectiveness; Evaluation of ARV Delivery and Coverage
- New Treatments and Targets
- Opportunistic Infections
  - Tuberculosis; Others
- Treating Target Populations
  - Adolescents and Children; Women; Late Presenters; Naïve Patients; Primary Infection; Experienced Patients; IDUs
- Treatment Strategies
  - Adherence; Cure; Simplification; Switch Studies
- Viral Hepatitis
- Virology and Immunology
  - Biomarkers; Tropism; Resistance; Other

Joint Academic Sponsors
The programme is of interest to clinical investigators from across the globe to review current research and to discuss its implications for HIV management strategies. Although there has been steady progress in HIV drug treatment, significant challenges still remain. In addition to looking at these treatment issues, the Congress is moving into areas, such as prevention, with time in the programme focused on pre-exposure prophylaxis (PrEP) and issues across Europe and beyond. The important role of people living with HIV in treatment decisions and self-management continues to feature, and we look forward to a number of perspectives in the programme from the community.